It is associated with major comorbidities, such as type 2 diabetes prostatic adenoma complications, ischemic heart disease, hypertension, dyslipidemia, sleep apnea, osteoarthritis, nonalcoholic fatty liver disease and depression.
The obesity pathogenesis increasingly became clearer. It is thought to be the result of a neuroendocrine dysregulation of energy intake and energy expenditure.
One of the most studied cytokines involved in obesity, leptin is secreted from adipose tissue, proportional to fat mass. Dopamine agonists DA prevent tumor growth, but usually suppress prolactin PRL both in mother and fetus. Possible long-term consequences on fetal development remain unknown.
Loiko ; Alexander V. Konkolovich; Alexander A.
Other 26 pregnancies in 21 patients were incompletely evaluated and included only in the pregnancy outcome and cure rate analysis. Treated patients were compared with the control group Y 8 women with PRM who discontinued DA after pregnancy induction 9 pregnancies and a control group Z of 46 healthy pregnant women, randomly selected from two departments of Obstetrics.
Patients with multiple pregnancies were recorded in each corresponding study group. Two patients with PRM-induced neuroophthalmic syndrome were successfully treated with DA throughout 1 and respectively 3 pregnancies.
Maintaining physiological serum PRL levels during pregnancy frequently with low doses of DA prevented tumor growth, avoiding a PRL suppression that may have subtle influence on long-term foetal development.
Radiological evidence for regression of prolactinoma after treatment with bromocriptine.
Lancet ; 2 Effects of bromocriptine on pituitary tumour size. Br Med J ; 2 Treatment of prolactinomas.
- Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX| Publications | Spie
- Cum afectează prostatita?
Ann Med ; 30 5 Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect. Endocrinologie ; 21 3 Schlechte JA. Clinical practice.
N Engl J Med ; 21 Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal.
J Clin Endocrinol Metab ; 87 8 Additional effects of radiotherapy to dopamine agonists in the treatment of macroprolactinomas. Acta Endocrinologica Buc ; 1 1 Withdrawal of longterm cabergoline therapy for tumoral and nontumoral hyperprolactinemia. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol ; 10 4 Pregnancy outcome after cabergoline treatment in early weeks of gestation.
Reprod Toxicol ; 16 6 Pregnancy induced and maintained under 2-Br-alfa-ergocryptin in a patient with evolutive prolactinoma in Romanian.
Timisoara Medical Journal
Obstetrica si Ginecologia ; Drugs in pregnancy and lactation. Dynamics of human chorionic gonadotropin, prolactin, and growth hormone in serum and amniotic fluid throughout normal human pregnancy. Am J Obstet Gynecol ; 7 Ben Jonathan N, Hnasko R. Dopamine as a prolactin PRL inhibitor. Endocr Rev ; 22 6 A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in prostatic adenoma complications maternal, fetal, and amniotic compartments.
Handwerger S, Freemark M. Role of placental lactogen and prolactin in human pregnancy. Adv Exp Med Biol ; Early pregnancy loss.
Archive of Clinical Cases
Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. Radiology ; 2 Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging.
Benign Prostatic Hyperplasia vs Prostate Cancer
Am J Med ; 85 prostatic adenoma complications The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc ; 65 4 Visual loss in pregnant women with pituitary adenomas.
Ann Intern Med ; 7 Molitch ME. Pregnancy and the hyperprolactinemic woman. Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine.
Neuromed 9 1. The procedures enable the determination of the thyroid gland size, of the thyroid parenchyma structure and vascularization, highlights the focal or diffuse lesions, makes the difference between the cyst and the solid lesions, as well as between the benign and malignant thyroid nodule, highlights the local adenopathies, makes the difference between a thyroid nodule and a cervical mass of a different origin. It is non-irradiating, noninvasive, it can be repeated, enables the fine needle biopsy, is useful in postoperative monitoring of the recurrence in patients with thyroid cancer surgery. The thyroid ultrasound is used in the percutaneous treatment with ethanol in case of the toxic adenomatous thyroid nodules. It is useful to diagnose the thyroid colloid cysts, thyroid goiter, thyroid cancer, acute, subacute or chronic thyroid, autoimmune or non-autoimmune thyroid.
Br J Obstet Gynaecol ; 91 8 Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol ; 8 Tumor size changes in prolactinomas treated with minimum bromocriptine throughout gestation. Gynecological Endocrinology ; 14 suppl 2 Bromocriptine as prophylactic therapy in prolactinoma during pregnancy.
Fertil Steril ; 36 4 Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy.
ACTA ENDOCRINOLOGICA (BUC)
Gynecol Endocrinol ; 10 2 Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary ; 4 3 Pediatr Med Chir ; 25 3 Cabergoline in the treatment of hyperprolactinemia: a study in patients. J Clin Endocrinol Metab ; 84 7 Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma.
J Endocrinol Invest ; 22 5 Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumorous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Inves Cabergoline treatment for a large macroprolactinoma throughout pregnancy.
J Obstet Gynaecol ; 17 4 Divers WA, Jr. Prolactin-producing microadenomas in pregnancy. Obstet Gynecol ; 62 4 Women with prolactin-producing pituitary adenoma show decreased serum placental lactogen during pregnancy.
Gynecol Obstet Invest ; 35 2 Prolactin-releasing system in maternal, fetal, and amniotic compartments during labor. Obstet Gynecol ; 68 1 Inhibition of human chorionic gonadotropin production by prolactin from term human trophoblast.
Am J Obstet Gynecol ; 2 Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol ; 3